RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Warrants for shortsLet's face it TLT will not be bought out while being a $0.36 stock. There will be some intermediate price it gets to before any offer is made and that's why I think we will see some bump before the next report. There are catalysts for that bump and with any further approval from the FDA a second and/or third Phase 1b trial will be announced. It is then that I think we are on the clock because with the success of NMIBC, efficacy and safety, the early results from those trials will have added weight - if not from the FDA who have more rigid responsibility then the big pharma suitors who will want to be first in line and therefore create a bidding war. I have seen stocks that trade above the takeout price just on the speculation of competing offers that may never come!
That might be fantasy but it's my opinion and one thing I would like to dispel is this thought about a lowball buyout. Most people talk about buyouts based on their own personal needs or wants and based on their average cost or the size of their position and then do the math from there but in reality they are based on value or at least perceived value.
I think it's the perceived value that ensures we don't even get a lowball offer never mind accept one. I wouldn't want to be the one trying to put a value on this if my above scenario plays out and they start to get good early data from further indications. Then there is the covid wildcard.
This is probably the best two weeks we've had in two years because of the move and the volume to back it up. I like talk of buyouts and while I think still premature, not by years and possibly months, nobody is getting this company on the cheap.